Literature DB >> 28280980

Emergencies in motoneuron disease.

Josef Finsterer1, Claudia Stöllberger2.   

Abstract

Genetic and acquired motor-neuron-disorders (MNDs) may undergo acute deterioration resulting in various emergency situations. This literature review aims at summarising and discussing current knowledge about emergencies in MNDs. Emergencies that have been reported in MND patients include: respiratory, bulbar, cardiac, septic, epileptic, psychiatric, pain-related, and traumatic emergencies. Emergencies due to respiratory insufficiency have the strongest impact on morbidity and mortality in MNDs. To optimise the management of emergencies in MNDs, it is recommended to discuss these topics with the patient prior to their occurrence. After informed consent, patients may indicate their decision by signing an advance directive as to how such emergencies should be managed in case they arise. Generally, treatment of emergencies in MNDs is not at variance from treatment of similar emergencies due to other causes, but some peculiarities need to be pointed out. It is concluded that patients with MNDs may experience various emergencies during the disease course. Management of these conditions should be discussed with the patient prior to their appearance. Management of these emergencies follows general guidelines, which widely vary between countries, and depend on the availability of a patient's advance directive.

Entities:  

Keywords:  Anterior horn cell disease; Artificial ventilation; Emergency; Motoneuron disease; Respiratory insufficiency; Seizures; Sepsis; Takotsubo

Mesh:

Year:  2017        PMID: 28280980     DOI: 10.1007/s11739-017-1644-6

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  83 in total

1.  Adrenoleukodystrophy associated with psychosis.

Authors:  L C Kopala; S Tan; C Shea; H Orlik; R Vandorpe; W G Honer
Journal:  Schizophr Res       Date:  2000-10-27       Impact factor: 4.939

2.  RETRACTED: Etidronate for fracture prevention in amyotrophic lateral sclerosis: a randomized controlled trial.

Authors:  Yoshihiro Sato; Yoshiaki Honda; Jun Iwamoto
Journal:  Bone       Date:  2006-06-14       Impact factor: 4.398

3.  Amyotrophic lateral sclerosis accompanying elevated catecholamines occurring as a complication of takotsubo cardiomyopathy.

Authors:  Yutaka Suzuki; Minoru Oishi; Akira Kanno; Katsuhiko Ogawa; Mariko Fujisawa; Satoshi Kamei
Journal:  Geriatr Gerontol Int       Date:  2013-01       Impact factor: 2.730

4.  EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force.

Authors:  Peter M Andersen; Sharon Abrahams; Gian D Borasio; Mamede de Carvalho; Adriano Chio; Philip Van Damme; Orla Hardiman; Katja Kollewe; Karen E Morrison; Susanne Petri; Pierre-Francois Pradat; Vincenzo Silani; Barbara Tomik; Maria Wasner; Markus Weber
Journal:  Eur J Neurol       Date:  2011-09-14       Impact factor: 6.089

Review 5.  Assessment and treatment of the risk of psychosis in adolescents--a review.

Authors:  Nicolas Zdanowicz; Laurence Mees; Denis Jacques; David Tordeurs; Christine Reynaert
Journal:  Psychiatr Danub       Date:  2014-06       Impact factor: 1.063

Review 6.  Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease.

Authors:  Reto Baldinger; Hans Dieter Katzberg; Markus Weber
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

7.  Current issues in the respiratory care of patients with amyotrophic lateral sclerosis.

Authors:  Marco Orsini; Agnaldo José Lopes; Sara Lucia Silveira de Menezes; Acary Bulle Oliveira; Marcos Raimundo Gomes de Freitas; Osvaldo Jose Moreira do Nascimento; Fernando Silva Guimarães
Journal:  Arq Neuropsiquiatr       Date:  2015-09-01       Impact factor: 1.420

8.  Alpha-locus hexosaminidase genetic compound with juvenile gangliosidosis phenotype: clinical, genetic, and biochemical studies.

Authors:  W G Johnson; C S Cohen; A F Miranda; S P Waran; A M Chutorian
Journal:  Am J Hum Genet       Date:  1980-07       Impact factor: 11.025

9.  Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2.

Authors:  A Reghan Foley; Manoj P Menezes; Amelie Pandraud; Michael A Gonzalez; Ahmad Al-Odaib; Alexander J Abrams; Kumiko Sugano; Atsushi Yonezawa; Adnan Y Manzur; Joshua Burns; Imelda Hughes; B Gary McCullagh; Heinz Jungbluth; Ming J Lim; Jean-Pierre Lin; Andre Megarbane; J Andoni Urtizberea; Ayaz H Shah; Jayne Antony; Richard Webster; Alexander Broomfield; Joanne Ng; Ann A Mathew; James J O'Byrne; Eva Forman; Mariacristina Scoto; Manish Prasad; Katherine O'Brien; Simon Olpin; Marcus Oppenheim; Iain Hargreaves; John M Land; Min X Wang; Kevin Carpenter; Rita Horvath; Volker Straub; Monkol Lek; Wendy Gold; Michael O Farrell; Sebastian Brandner; Rahul Phadke; Kazuo Matsubara; Michael L McGarvey; Steven S Scherer; Peter S Baxter; Mary D King; Peter Clayton; Shamima Rahman; Mary M Reilly; Robert A Ouvrier; John Christodoulou; Stephan Züchner; Francesco Muntoni; Henry Houlden
Journal:  Brain       Date:  2013-11-19       Impact factor: 13.501

10.  A novel lamin A/C gene mutation causing spinal muscular atrophy phenotype with cardiac involvement: report of one case.

Authors:  Naotoshi Iwahara; Shin Hisahara; Takashi Hayashi; Jun Kawamata; Shun Shimohama
Journal:  BMC Neurol       Date:  2015-02-20       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.